Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2007-08-27 Major Shareholding Noti…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Becoming a substantial holder 2 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 under the Corporations Act 2001, titled 'Notice of Initial Substantial Holder.' It details the substantial shareholding of Acorn Capital Limited in Pharmaxis Ltd, including voting power, relevant interests, registered holders, consideration paid, and associates. This type of filing is a notification of a major shareholding event, specifically the initial substantial holder notice. It is not a financial report, management announcement, or other types of filings. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is the actual notification, not an announcement or reference to another report.
2007-08-27 English
Updated Investor Presentation 31 pages ?Kb
Investor Presentation Classification · 95% confidence The document is an investor presentation dated August 2007, discussing therapeutic products, development pipeline, and market information related to respiratory and autoimmune diseases. It contains forward-looking statements, product descriptions, and market data, typical of presentations aimed at investors. There is no indication of detailed financial statements, audit information, or regulatory filings. The length is about 15,000 characters, consistent with a detailed presentation rather than a brief announcement. Therefore, the document fits the category of an Investor Presentation (IP).
2007-08-14 English
Proposed Issue of Options 2 pages ?Kb
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement addressed to the Australian Stock Exchange regarding the proposed issue of securities in the form of employee options and options to an executive director. It references compliance with Listing Rule 3.10.3 and details the number, terms, and approval status of the options to be issued. There is no financial data, earnings information, or detailed report content. The document is an announcement about a capital change (issue of securities) rather than a full report or financial statement. Therefore, it fits best under the category for announcements related to new share issues or capital changes.
2007-08-12 English
Appendix 3B 10 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements. The content details the issuance of unlisted employee options, exercise prices, expiry dates, vesting schedules, and the purpose of the issue. It also includes information about the number of securities quoted and not quoted on ASX. This type of document is a capital/financing update as it relates to changes in the company's capital structure through the issuance of new securities. It is not a full financial report, earnings release, or management discussion, nor is it a regulatory filing or announcement of a report publication. Therefore, the correct classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2007-08-12 English
Preliminary Final Report 38 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'ASX Preliminary final report – 30 June 2007' and references the year ended 30 June 2007, indicating it covers a full fiscal year. It includes detailed financial statements such as income statements, balance sheets, cash flow statements, and notes to the financial statements. The document also mentions it is lodged under ASX Listing Rule 4.3A, which pertains to preliminary final reports in Australia. The content includes comprehensive financial data, management commentary, audit status, and detailed operational results, all characteristic of an annual report. The length of the document (15,000 characters) and the presence of full financial statements confirm it is the report itself, not just an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K equivalent). FY 2007
2007-08-09 English
Quarterly Report to Shareholders 8 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Report to Shareholders' and covers the period April to June 2007. It includes detailed operational updates, clinical trial progress, regulatory approvals, marketing activities, research partnerships, intellectual property status, and a financial overview with specific figures such as cash balances, sales, margins, and expenses for the quarter. The content is comprehensive and includes substantive financial data and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is IR with high confidence. Q4 2007
2007-08-05 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.